Male Vitality Supplements: A Clinical Guide to Optimising Hormonal and Cellular Health

Most discussions of men's vitality and testosterone decline begin with the number: the approximately 1% per year decline in total serum testosterone that epidemiological data, including the Handelsman 2020 Australian cohort, documents in men from their mid-30s onward. This is a real phenomenon with real clinical consequences. What these discussions rarely provide is the molecular explanation — the specific cellular machinery whose progressive impairment drives that decline, and through which nutritional interventions can exert mechanistically grounded support. The machinery in question begins not with a hormone but with a protein that most men have never heard of: the Steroidogenesis Acute Regulatory (StAR) protein, whose activity within the Leydig cells of the testes constitutes the actual rate-limiting step of testosterone biosynthesis — and whose function depends directly on the mitochondrial membrane potential that CoQ10 maintains.

Understanding StAR protein establishes the first principle of mechanistically coherent men's vitality supplementation: supporting testosterone production is not fundamentally about providing testosterone precursors or stimulating LH signalling. It is about maintaining the mitochondrial capacity that Leydig cell steroidogenesis requires at its molecular foundation. This reframing opens a clinical picture of male hormonal health that is considerably more nuanced than total serum testosterone measurements alone reveal — one that includes the SHBG dynamics that determine how much of any testosterone produced is actually bioavailable to tissues, the sperm mitochondrial architecture whose function determines fertility parameters independently of hormonal status, and the oxidative mechanisms that impair both steroidogenesis and sperm DNA integrity in ways that specific antioxidant nutrients address with documented, measurable efficacy. This article covers five dimensions of male vitality biology that have not been addressed as primary subjects in the Zenutri article series, mapping each to the TGA-listed formulations whose mechanisms are directly relevant.

StAR Protein, Leydig Cell Steroidogenesis, and the Mitochondrial Foundation of Testosterone

Testosterone biosynthesis in Leydig cells follows a pathway that is well understood in outline: cholesterol → pregnenolone → progesterone → androstenedione → testosterone, catalysed by a sequence of cytochrome P450 and hydroxysteroid dehydrogenase enzymes. What is less commonly appreciated is where this pathway begins — not with an enzymatic reaction but with a transport event that is both essential and rate-limiting, and that takes place not in the cytoplasm or smooth endoplasmic reticulum where most steroidogenic enzymes operate but in the mitochondria. The first committed enzymatic step — the conversion of cholesterol to pregnenolone by CYP11A1 (cytochrome P450 side chain cleavage enzyme) — occurs on the inner mitochondrial membrane. Cholesterol, the substrate, is abundant in the cytoplasm and outer mitochondrial membrane. But cholesterol cannot spontaneously cross the 10-20nm intermembrane space between the outer and inner mitochondrial membranes — its hydrophobicity and the aqueous nature of the intermembrane space make passive diffusion negligible. The molecule that physically shuttles cholesterol across this gap is StAR protein.

StAR (Steroidogenesis Acute Regulatory protein) is a mitochondria-targeting protein expressed at high levels in steroidogenic cells that docks at the outer mitochondrial membrane, associates with a transduceosome complex of proteins including TSPO (translocator protein, the peripheral benzodiazepine receptor), and facilitates the rapid, LH-stimulated import of cholesterol to the CYP11A1 enzyme on the inner membrane. StAR's activity responds acutely to LH signalling from the pituitary — it is the molecular mechanism through which LH's second-messenger cascade (cAMP → PKA → StAR gene transcription and protein phosphorylation) translates hormonal stimulation into actual steroid production. In congenital lipoid adrenal hyperplasia, where StAR protein is absent due to genetic mutation, testosterone cannot be synthesised despite normal cholesterol availability and intact downstream enzymatic machinery — illustrating that StAR is not merely facilitatory but essential. The rate at which StAR protein can transport cholesterol to CYP11A1 is, therefore, the biological ceiling on Leydig cell testosterone output under any given LH stimulation.

The critical but rarely discussed connection to mitochondrial bioenergetics is this: StAR protein function and the transduceosome complex that supports it require an intact mitochondrial membrane potential — the proton gradient across the inner mitochondrial membrane generated by the electron transport chain's proton pumping activity. Collapse of the mitochondrial membrane potential (through ETC Complex I or III dysfunction, through oxidative mtDNA damage, or through CoQ10 insufficiency reducing electron shuttling efficiency) impairs cholesterol import to CYP11A1 independently of LH signalling or cholesterol availability. Aging Leydig cells show well-documented mitochondrial structural deterioration — accumulation of oxidised mtDNA, reduced ETC complex activity, and declining CoQ10 concentrations — that reduces their steroidogenic capacity through precisely this mitochondrial membrane potential mechanism. The implication for men's vitality supplementation is direct: CoQ10 (UbiQ Forte, AUST L 520795, 150mg) and NAD+ restoration for SIRT3-mediated ETC complex deacetylation and mitochondrial function (Reversa NR, AUST L 520794, 150mg NR) support the mitochondrial infrastructure that StAR-dependent Leydig cell steroidogenesis requires — not as generic "energy supplements" but through a specific, mechanistically documented pathway that links mitochondrial membrane potential to testosterone production capacity. The energy and fatigue article covers the ETC architecture in detail; in the context of Leydig cells, this architecture serves as the molecular foundation of male hormonal health.

Vitamin D3 and the Steroidogenic Pathway: VDR in Leydig Cells

The connection between Vitamin D3 and male testosterone is mechanistically grounded in the Vitamin D receptor (VDR) expression in Leydig cells. Population data from the Handelsman cohort and subsequent analysis consistently shows a correlation between 25(OH)D below 50 nmol/L and lower total and free testosterone in Australian men — but the molecular mechanism was not simply correlation until the identification of VDR in Leydig cells and the VDR response elements in the promoter regions of StAR and CYP17A1 (the 17α-hydroxylase enzyme in the testosterone pathway). Calcitriol-activated VDR upregulates StAR gene expression in Leydig cells — providing a direct genomic mechanism through which Vitamin D3 status influences the rate-limiting step of testosterone synthesis that we identified above. This is the specific mechanism behind the clinical observation, and it makes Osteo+Core (AUST L 520792) at 1,000 IU D3 morning dosing not merely a bone and immune formulation but a steroidogenic pathway support nutrient in men with confirmed insufficiency. Take the free Zenutri health quiz to understand where Vitamin D fits in your complete men's vitality profile.

SHBG Dynamics: The Metabolic Drivers of Free Testosterone Decline

A man in his late 40s visits his GP, reports classic andropause symptoms — persistent fatigue, morning cognitive blunting, reduced recovery from training, declining libido — and receives a total testosterone result of 14 nmol/L, within the 8-29 nmol/L laboratory reference range. His GP tells him his testosterone is normal. His symptoms remain unexplained. What neither he nor his GP may have considered is that his SHBG has risen to 55 nmol/L (the upper end of the reference range), binding 98% of his circulating testosterone into a biologically inactive complex — leaving a free testosterone of approximately 0.28 nmol/L, below the lower quartile of his age group. The total testosterone measurement confirmed adequate production. The free testosterone measurement would have revealed the real clinical picture. This SHBG-mediated discrepancy between total and bioavailable testosterone is among the most clinically consequential and most commonly overlooked mechanisms of andropause, and it is entirely addressable through metabolic interventions — because SHBG is not a fixed physiological parameter but a hepatic protein whose production is dynamically regulated by the same metabolic drivers that define the health trajectory of middle-aged Australian men.

SHBG is synthesised by hepatocytes and its production is regulated by multiple transcription factors whose activity is modulated by metabolic state. The most clinically significant upregulators of SHBG production in the context of men's health are: hyperinsulinaemia and insulin resistance (insulin directly suppresses hepatic SHBG production at low concentrations but paradoxically drives higher SHBG when hepatic insulin resistance decouples the insulin suppression signal); hepatic NF-κB activation from systemic inflammation (the same inflammatory transcription factor that curcumin inhibits — covered in the anti-ageing article); and oestradiol, which is itself upregulated in men with central adiposity through increased aromatase activity in visceral adipose tissue converting testosterone to oestradiol. This third mechanism produces a compound effect that explains why weight gain in men over 40 so reliably accelerates the free testosterone decline: the aromatase in visceral fat simultaneously reduces total testosterone (by converting it to oestradiol) and elevates SHBG (through oestradiol's hepatic SHBG-stimulating effect) — reducing free testosterone from both the numerator and the denominator of the free fraction calculation simultaneously.

Alpha-Lipoic Acid, Insulin Sensitivity, and the SHBG Pathway

Alpha-lipoic acid (ALA) — the mitochondrial redox co-factor in MagLipo Core (AUST L 520793) at 150mg — is the most direct nutritional intervention on the insulin resistance driver of SHBG upregulation available within the Zenutri range. ALA's insulin-sensitising mechanism operates through AMPK (AMP-activated protein kinase) activation, which mimics the exercise signal to increase GLUT4 transporter translocation to cell membranes in skeletal muscle and adipose tissue — improving glucose uptake and reducing the hyperinsulinaemia that drives SHBG dysregulation. The Packer, Witt, and Tritschler 1995 Free Radical Biology and Medicine research establishes ALA's position as both a network antioxidant and a metabolic co-factor; the AMPK-GLUT4 insulin sensitisation mechanism of ALA provides the specific hepatic SHBG connection that makes MagLipo Core's ALA component relevant to free testosterone bioavailability rather than simply antioxidant protection. Curcumin-piperine (CurcuNova, AUST L 520796) addresses the NF-κB hepatic inflammation arm of SHBG upregulation simultaneously — making the combination of CurcuNova and MagLipo Core the most mechanistically complete nutritional intervention on SHBG dynamics available within the TGA-listed Zenutri range. Note: CurcuNova is contraindicated for users of antidepressant medications metabolised by CYP3A4 (piperine inhibition) and requires GP discussion for warfarin users.

Sperm Mitochondrial Midpiece, CoQ10, and Axonemal Dynein Motility

The human sperm cell has one of the most specialised cellular architectures in the body — a design optimised for a single mechanical purpose: directed forward movement through the female reproductive tract across a distance that, scaled to the sperm cell's size, is equivalent to a human swimming across several kilometres through a viscous medium. The mechanical engine of this movement is the sperm flagellum — an axoneme (central core structure) composed of nine outer microtubule doublets surrounding two central microtubules in the classic 9+2 arrangement. Movement is generated by dynein motor proteins that bridge adjacent outer doublet pairs, hydrolyse ATP in a power stroke that slides the doublets relative to each other, and produce the coordinated bending wave that drives the flagellar beat. The dynein molecules are ATPases — their motility output is directly proportional to ATP supply at the dynein active site.

The sperm cell sources this ATP from two locations depending on flagellar region. In the principal piece — the long distal flagellum — glycolysis in the fibrous sheath cytoplasm produces ATP through anaerobic fermentation of glucose. In the midpiece — the proximal 5-7 micrometres of the flagellum immediately behind the sperm head — approximately 75 mitochondria are arranged in a precise helical sheath around the axonemal core, generating ATP through oxidative phosphorylation. The mitochondrial OXPHOS contribution is disproportionately important for the high-velocity, straight-line progressive motility (Type A motility) that is most predictive of fertilisation capacity: in vitro studies have consistently shown that mitochondrial uncouplers or ETC inhibitors selectively impair progressive motility while leaving total motility partially preserved, because the mitochondrial ATP is specifically required for the sustained, directional axonemal activity that the principal piece glycolysis alone cannot maintain for the duration of the reproductive journey. CoQ10 is concentrated in human sperm at levels substantially above those in most other tissues — particularly in the mitochondrial midpiece — reflecting the extraordinary ETC demand of the helical sheath's constant OXPHOS activity during motile sperm function.

The clinical evidence is provided by the Balercia 2009 randomised, double-blind, placebo-controlled trial published in Fertility and Sterility, which enrolled 212 infertile men with idiopathic oligoasthenozoospermia (reduced sperm count and motility without an identified cause) and randomly assigned them to CoQ10 200mg daily or placebo for 26 weeks. The CoQ10 group showed statistically significant improvements in sperm progressive motility (the parameter most directly reflecting the axonemal dynein ATP supply mechanism), straight-line velocity, and linearity — the parameters corresponding to the mitochondrial midpiece's ETC contribution to forward movement. The mechanism was confirmed by the correlation between improvements in seminal plasma CoQ10 concentrations and improvements in motility parameters, establishing a direct dose-response relationship. UbiQ Forte (AUST L 520795) provides CoQ10 at 150mg — within the range producing clinical sperm motility effects and simultaneously addressing the systemic mitochondrial and Leydig cell steroidogenic mechanisms described above, making it the single most cross-mechanistically relevant formulation in the Zenutri men's vitality range. The longevity blueprint article covers the PINK1-Parkin mitophagy mechanism, by which CoQ10 supports mitochondrial quality control; in the sperm context, this mitochondrial quality control directly determines the ETC efficiency required for motility.

Sperm DNA Fragmentation, 8-OHdG, and the Epididymal Antioxidant System

Standard semen analysis — the WHO-defined parameters of count, total motility, progressive motility, and morphology — has been the clinical standard for male fertility assessment for decades. An increasingly recognised limitation of this framework is that it evaluates the physical and mechanical properties of sperm cells without assessing the integrity of their genetic cargo. Sperm DNA fragmentation — the presence of single-strand or double-strand breaks in the sperm DNA that will eventually form half the genetic complement of an embryo — is a dimension of sperm quality that standard semen analysis is structurally incapable of detecting, yet that is consistently associated with reduced natural conception rates, reduced IVF success rates, and elevated risk of miscarriage. The DNA fragmentation index (DFI) — measured by sperm chromatin structure assay (SCSA) or terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) — quantifies the percentage of sperm with fragmented DNA; DFI above 15-25% is generally considered a clinically significant finding associated with impaired fertility outcomes.

The primary mechanism of sperm DNA damage is oxidative — specifically, the reaction of hydroxyl radical (•OH, generated from hydrogen peroxide by Fenton chemistry involving intracellular iron) with the guanine base of DNA to produce 8-hydroxy-2'-deoxyguanosine (8-OHdG). 8-OHdG is both a mutagenic DNA lesion (because 8-oxoguanine is misread as thymidine by DNA polymerase during replication, producing G:C to T:A transversion mutations) and a validated biomarker of oxidative DNA damage burden. Sperm cells are uniquely vulnerable to oxidative DNA damage because: mature sperm contain very little cytoplasmic antioxidant enzyme activity (cytoplasm is stripped during spermiogenesis to reduce cell volume for hydrodynamic efficiency); sperm DNA is highly compacted into protamine-replaced nucleosomes that reduce repair enzyme access; and sperm spend 2-12 days in the epididymis — a relatively oxidative microenvironment — before ejaculation, during which cumulative oxidative damage to DNA can accumulate if epididymal antioxidant protection is inadequate.

GPx5 and the Epididymal Antioxidant Barrier

The primary antioxidant defence of sperm DNA during epididymal transit is provided by glutathione peroxidase 5 (GPx5) — an extracellular glutathione peroxidase expressed exclusively by the epididymal epithelium and secreted into the epididymal lumen, where it reduces hydrogen peroxide and lipid peroxides in the immediate microenvironment surrounding the transiting sperm. GPx5, unlike the classical GPx1-4 family members, does not contain selenocysteine — it is a cysteine-dependent peroxidase rather than a selenoprotein. However, its glutathione substrate is recycled by glutathione reductase, which relies on NADPH, which is generated by the pentose phosphate pathway using Vitamin C (ascorbate) as a cofactor. Additionally, the broader epididymal antioxidant system includes GPx4 (the selenoprotein covered in detail in the immune support article) in the midpiece mitochondria, which specifically reduces phospholipid hydroperoxides in the sperm plasma membrane — protecting the structural integrity of the acrosome and midpiece from lipid peroxidation chain reactions that correlate with elevated DFI. Selenomethionine (Immunaxis, AUST L 521494, 100mcg) provides the selenium substrate for GPx4's selenoprotein active site in sperm mitochondria; Vitamin C (C E B Optima, AUST L 521487, 250mg) and natural mixed tocopherols (70mg) provide the lipid-phase and aqueous-phase antioxidant network protection that limits hydroxyl radical availability for 8-OHdG formation; and zinc glycinate (Immunaxis, 20mg) supports the zinc-containing superoxide dismutase (Cu/Zn-SOD) in seminal plasma that provides the upstream O₂•⁻ to H₂O₂ conversion that GPx then reduces — creating a coordinated three-stage antioxidant cascade that reduces the 8-OHdG burden in sperm DNA. For Australian men with elevated DFI identified by sperm chromatin testing, this antioxidant protocol addresses the most prevalent mechanism of DNA fragmentation through three complementary molecular pathways, rather than a single-ingredient approach.

The Zenutri Men's Vitality Protocol: Four Mechanisms, One Clinical Framework

The appropriate starting point for any men's vitality supplement protocol is pathology, not supplementation. Request from your GP before initiating: total testosterone (2 morning samples, ideally before 10am when diurnal testosterone is highest), free testosterone or calculated free testosterone from SHBG, SHBG, LH, FSH, and 25(OH)D. This panel costs less than most supplement regimens and takes 10 minutes to request — yet it provides the diagnostic clarity that separates the andropause (nutritionally addressable) from the clinical hypogonadism (TRT-indicated) presentation. If free testosterone is low-normal with elevated SHBG, if LH is normal or mildly elevated, and if 25(OH)D is below 50 nmol/L, this is the clinical profile for which the four-mechanism nutritional protocol below has the most directly relevant mechanistic support.

Morning (with fat-containing meal — CoQ10, NR, and D3 require lipid co-absorption):

UbiQ Forte (AUST L 520795) — CoQ10 150mg.

Addresses: Mitochondrial membrane potential for StAR protein Leydig cell cholesterol transport; sperm midpiece OXPHOS for axonemal dynein Type A progressive motility (Balercia 2009, Fertility and Sterility); PINK1-Parkin mitophagy quality control in Leydig cell and sperm midpiece mitochondria. Safety: warfarin users — modest anticoagulant interaction, GP discussion warranted; CoQ10 may reduce insulin requirements slightly in type 2 diabetes — monitor if on insulin or sulfonylurea.

Reversa NR (AUST L 520794) — NR 150mg, Resveratrol 75mg, Mg chelate 55mg, BioPerine 6.95mg.

Addresses: NAD+/SIRT3 mitochondrial deacetylation for ETC complex function (supporting Leydig cell StAR activity); SIRT1 deacetylation of androgen receptor (AR) co-activators; SIRT1-FOXO transcription factor regulation of steroidogenic enzyme expression. Safety: antidepressant users — piperine CYP3A4 interaction, GP consultation required; warfarin — discuss; pregnancy PAUSE.

Osteo+Core (AUST L 520792) — D3 1,000 IU, K2-MK7 180mcg.

Addresses: VDR-mediated StAR and CYP17A1 gene expression in Leydig cells for steroidogenic capacity; D3 serotonin synthesis support for testosterone-mood co-regulation; K2 vascular calcification protection (cardiovascular health underpins sustained perfusion of testicular tissue). Morning timing. K2 — warfarin GP discussion.

Evening (with meal or small snack):

MagLipo Core (AUST L 520793) — Mg amino acid chelate 55mg elemental, ALA 150mg.

Addresses: ALA AMPK activation improving insulin sensitivity and reducing SHBG upregulation; magnesium NMDA antagonism supporting deep slow-wave sleep (the principal period of pulsatile LH secretion and overnight testosterone synthesis); ALA network antioxidant recycling reducing Leydig cell and sperm oxidative DNA damage burden. ALA — confirm with GP if on antidiabetic or thyroid medication.

Immunaxis (AUST L 521494) — Zinc glycinate 20mg, Selenomethionine 100mcg, Vit A 900mcg RE.

Addresses: Zinc-thymulin and zinc TRAF6 immune support; zinc Cu/Zn-SOD seminal plasma antioxidant (sperm DNA protection); zinc 5α-reductase inhibition moderating DHT conversion in peripheral tissues; selenomethionine GPx4 selenoprotein for sperm midpiece mitochondrial membrane protection and epididymal sperm DNA integrity. Selenium 100mcg — within NHMRC 150mcg/day UL; monitor cumulative sources.

C E B Optima (AUST L 521487) — Vit C 250mg, Mixed tocopherols 70mg, Nicotinamide 125mg.

Addresses: Ascorbate aqueous-phase antioxidant reducing hydroxyl radical availability for 8-OHdG sperm DNA oxidation; mixed tocopherols lipid-phase protection of sperm acrosome and midpiece membranes; ascorbate-tocopherol network antioxidant regeneration cycle; nicotinamide NAD+ Preiss-Handler pathway for complementary Leydig cell mitochondrial support.

The most streamlined entry point for Australian men with a performance and energy focus is the Zenutri Peak Performance Stack (Reversa NR AUST L 520794 + UbiQ Forte AUST L 520795 + MagLipo Core AUST L 520793 + C E B Optima AUST L 521487, $88 AUD) — addressing the StAR mitochondrial, SHBG metabolic, and sperm antioxidant mechanisms in four formulations. Adding Immunaxis for the zinc-selenium sperm DNA and steroidogenic dimension, and Osteo+Core for the D3 VDR Leydig cell mechanism, builds the complete six-formulation protocol. The Cellular Energy Support Bundle (UbiQ Forte + MagLipo Core, $43.50) provides the CoQ10-mitochondrial and ALA-SHBG entry point at lower cost for men prioritising the Leydig cell mitochondrial and insulin sensitivity mechanisms specifically.

For the cortisol-testosterone interaction covered in the draft article's HPA axis section — the pregnenolone competition and evening cortisol disruption of sleep-time testosterone synthesis — the ashwagandha article covers the withanolide GABAergic, glucocorticoid receptor, and Chandrasekhar 2012 cortisol reduction evidence in detail. KSM-66 ashwagandha addresses the HPA axis arm; the protocol above addresses the Leydig cell mitochondrial, SHBG metabolic, and sperm antioxidant arms — together covering the four most clinically consequential dimensions of male hormonal and reproductive health that nutritional interventions can meaningfully address. Take the free Zenutri health quiz to receive a personalised recommendation mapped to your age, confirmed pathology results, and specific vitality priorities.

Testosterone Is Manufactured in Mitochondria, Not in Marketing

The StAR protein's cholesterol transport function, the SHBG dynamics that determine bioavailable free testosterone from total production, the sperm midpiece's helical mitochondrial sheath generating the ATP that axonemal dynein requires for progressive motility, and the epididymal GPx5-selenium-Vitamin C antioxidant system protecting sperm DNA from 8-OHdG oxidative fragmentation — these are the molecular realities of male reproductive and hormonal health that effective men's vitality supplementation in Australia must address. The measurement that matters is not total testosterone on a lab report but the integrated biological capacity — mitochondrial, metabolic, antioxidant, and hormonal — that determines whether the testosterone being produced is reaching the tissues and cells that need it, and whether the genetic investment being made in every sperm cell is protected from the oxidative environment of the male reproductive tract. TGA-listed, bioavailability-optimised, therapeutically dosed formulations that address these mechanisms specifically are the standard that evidence-grounded men's vitality supplementation should be measured against.

Always read the label. Follow the directions for use. Supplements are not a substitute for a balanced diet. If symptoms persist, consult your healthcare professional. This article is for educational purposes and does not constitute individual medical advice. Male hormonal health requires GP-supervised pathology assessment before initiating any supplement protocol.

Explore the Zenutri Peak Performance Stack — the four-formulation StAR protein, SHBG, sperm mitochondrial, and antioxidant men's vitality protocol at $88 AUD — or take the free health quiz to receive a personalised men's vitality recommendation tailored to your pathology results and specific health priorities.

Frequently Asked Questions

What are the best men's vitality supplements in Australia?

The strongest evidence maps to CoQ10 at 150mg (UbiQ Forte AUST L 520795) for StAR protein Leydig cell mitochondrial function and sperm midpiece axonemal ATP; NR 150mg (Reversa NR AUST L 520794) for NAD+/SIRT3 ETC deacetylation and Leydig cell steroidogenic capacity; ALA 150mg and magnesium (MagLipo Core AUST L 520793) for insulin sensitivity-SHBG reduction and deep sleep LH pulsatility support; zinc glycinate 20mg and selenomethionine 100mcg (Immunaxis AUST L 521494) for GPx4 sperm mitochondrial antioxidant and 8-OHdG sperm DNA protection; and Vitamin C 250mg, mixed tocopherols 70mg (C E B Optima AUST L 521487) for network antioxidant sperm DNA integrity. Combined in the Peak Performance Stack ($88 AUD).

What is the StAR protein and why does it matter for testosterone?

StAR (Steroidogenesis Acute Regulatory) protein physically transports cholesterol from the outer to the inner mitochondrial membrane in Leydig cells — the rate-limiting step of testosterone synthesis that no enzymatic activity can proceed without. StAR function requires an intact mitochondrial membrane potential generated by the ETC. Declining CoQ10 in ageing Leydig cell mitochondria reduces membrane potential, impairs StAR transport, and limits testosterone output even when LH stimulation and cholesterol substrate are normal. UbiQ Forte CoQ10 at 150mg addresses this mitochondrial membrane potential mechanism directly — making it uniquely relevant to Leydig cell steroidogenesis rather than simply systemic energy.

What is SHBG and how does it reduce free testosterone?

SHBG (sex hormone-binding globulin) is a hepatic protein that binds 97-98% of circulating testosterone with high affinity, making it biologically inactive at tissue androgen receptors. Free testosterone — the bioavailable fraction — constitutes approximately 2-3% of total. SHBG is upregulated by insulin resistance (through hepatic AKT/FOXO1 pathway dysregulation), NF-κB hepatic inflammation, and visceral adipose aromatase-generated oestradiol. Total testosterone can remain within the statistical reference range while free testosterone declines significantly with SHBG elevation — producing andropause symptoms without a clinical hypogonadism diagnosis. ALA in MagLipo Core improves insulin sensitivity by activating AMPK, reducing the primary driver of SHBG upregulation. CurcuNova NF-κB inhibition addresses the inflammatory SHBG driver simultaneously.

How does CoQ10 help with sperm motility?

Sperm progressive motility (Type A) requires mitochondrial ATP production in the midpiece helical sheath of ~75 mitochondria for axonemal dynein motor activity. CoQ10 concentrated in sperm midpiece mitochondria maintains the ETC electron carrier function between Complex I-II and Complex III that generates the proton gradient for ATP synthase. The Balercia 2009 placebo-controlled RCT (212 infertile men, 200mg CoQ10 daily, 26 weeks) demonstrated significant improvements in progressive motility, straight-line velocity, and linearity — directly reflecting the midpiece OXPHOS contribution to forward movement. UbiQ Forte at 150mg provides this mechanism within the clinically supported dose range.

What causes sperm DNA fragmentation and how can supplements help?

Sperm DNA fragmentation is caused primarily by hydroxyl radical oxidation of guanine to 8-OHdG — a mutagenic DNA lesion linked to reduced fertilisation rates and elevated miscarriage risk. Sperm are vulnerable because they have minimal cytoplasmic antioxidant enzymes after spermiogenesis maturation. The primary epididymal protection is GPx5 (cysteine-dependent peroxidase secreted by epididymal epithelium) and GPx4 (selenoprotein in sperm midpiece). Selenomethionine 100mcg (Immunaxis) supports GPx4 selenoprotein active site; Vitamin C 250mg (C E B Optima) reduces H₂O₂ availability for Fenton hydroxyl radical generation; mixed tocopherols 70mg protect sperm membrane lipids from chain peroxidation; and zinc glycinate 20mg supports seminal plasma Cu/Zn-SOD upstream O₂•⁻ dismutation — together addressing the three-stage antioxidant cascade that determines sperm DFI.

What is andropause, and is it different from clinical hypogonadism?

Andropause (late-onset hypogonadism, age-related testosterone deficiency syndrome) describes the gradual symptomatic decline in men with total testosterone in the lower-normal range and elevated SHBG — producing genuine fatigue, cognitive blunting, and reduced recovery without meeting diagnostic criteria for TRT-indicated clinical hypogonadism (total testosterone below reference range with elevated LH/FSH). Clinical hypogonadism requires specialist endocrinology review and TRT consideration. Andropause — with low-normal total testosterone, elevated SHBG, and intact but declining free testosterone — is the primary target for nutritional interventions addressing Leydig cell mitochondrial function, SHBG metabolic drivers, and steroidogenic antioxidant protection. GP-supervised pathology (total and free testosterone, SHBG, LH, FSH, 25(OH)D) should precede any supplement protocol to determine which clinical picture applies.